IN2012DN01663A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01663A
IN2012DN01663A IN1663DEN2012A IN2012DN01663A IN 2012DN01663 A IN2012DN01663 A IN 2012DN01663A IN 1663DEN2012 A IN1663DEN2012 A IN 1663DEN2012A IN 2012DN01663 A IN2012DN01663 A IN 2012DN01663A
Authority
IN
India
Prior art keywords
seq
fragments
cancer
class
cea antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Hans J Hansen
Chien-Hsing Chang
David M Goldenberg
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of IN2012DN01663A publication Critical patent/IN2012DN01663A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
IN1663DEN2012 2009-09-16 2010-07-29 IN2012DN01663A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24287209P 2009-09-16 2009-09-16
PCT/US2010/043663 WO2011034660A1 (fr) 2009-09-16 2010-07-29 Anticorps anti-cea de classe i et leurs utilisations

Publications (1)

Publication Number Publication Date
IN2012DN01663A true IN2012DN01663A (fr) 2015-06-05

Family

ID=43730776

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1663DEN2012 IN2012DN01663A (fr) 2009-09-16 2010-07-29

Country Status (6)

Country Link
US (7) US8287865B2 (fr)
EP (2) EP2478110B1 (fr)
CN (1) CN102482701B (fr)
CA (1) CA2774260C (fr)
IN (1) IN2012DN01663A (fr)
WO (1) WO2011034660A1 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
EP1572131B1 (fr) * 2002-10-08 2016-07-06 Immunomedics, Inc. Therapie fondee sur les anticorps
US20100226884A1 (en) 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US9862770B2 (en) * 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US9272029B2 (en) 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
IN2012DN01663A (fr) 2009-09-16 2015-06-05 Immunomedics Inc
US9464136B2 (en) 2010-08-20 2016-10-11 Massachusetts Institute Of Technology Antibody-based constructs directed against tyrosine kinase receptors
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2981662C (fr) 2011-01-14 2019-02-05 The Regents Of The University Of California Anticorps therapeutiques contre la proteine ror-1 et leurs methodes d'utilisation
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
CN102911248B (zh) * 2011-08-05 2014-12-10 上海原子科兴药业有限公司 合成1，4-二取代三唑结构的188Re(CO)3标记化合物的方法
CA2861335A1 (fr) * 2012-01-26 2013-08-01 Ibc Pharmaceuticals, Inc. Ciblage d'interferon-lambda par des anticorps favorisant puissamment les activites antivirales et antitumorales.
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
CA2941485C (fr) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines et leurs conjugues
EA039377B1 (ru) * 2012-11-20 2022-01-20 Санофи Антитела к ceacam5 и их применения
JP6392770B2 (ja) 2012-12-03 2018-09-19 ノビミューン エスアー 抗ｃｄ４７抗体およびその使用方法
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US10329350B2 (en) 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
EP2968585B1 (fr) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
EP2970372B1 (fr) 2013-03-15 2020-09-30 Celgene Corporation Lymphocytes t modifiés
CN105324124A (zh) 2013-04-19 2016-02-10 赛腾制药 降低的血管渗漏综合征的细胞因子衍生治疗
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
US9349535B2 (en) 2013-12-17 2016-05-24 Metastable Materials, Inc. Method and apparatus for manufacturing isotropic magnetic nanocolloids by pulsed laser ablation
EP2915569A1 (fr) 2014-03-03 2015-09-09 Cytune Pharma Procédé de purification de conjugués à base Il -15/IL-15Ralpha
NZ726520A (en) 2014-05-29 2018-12-21 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
ES2892525T3 (es) 2014-10-07 2022-02-04 Immunomedics Inc Uso neoadyuvante de conjugados anticuerpo-fármaco
CA2973978A1 (fr) * 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Traitement du cancer avec des anticorps monoclonaux anti-lap
HUE048111T2 (hu) 2015-03-23 2020-05-28 Bayer Pharma AG Anti-CEACAM6 ellenanyagok és alkalmazásuk
ES2953441T3 (es) 2015-06-25 2023-11-13 Immunomedics Inc Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer
EP3316885B1 (fr) 2015-07-01 2021-06-23 Immunomedics, Inc. Immunoconjugués d'anticorps sn-38 avec un lieur cl2a
CN106432502B (zh) * 2015-08-10 2020-10-27 中山大学 用于治疗cea阳性表达肿瘤的双特异纳米抗体
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
WO2017107973A1 (fr) * 2015-12-24 2017-06-29 凯惠科技发展(上海)有限公司 Anticorps anti-tpbg et son procédé de préparation, conjugué et son utilisation
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
SG10201913326UA (en) 2016-06-07 2020-02-27 Macrogenics Inc Combination therapy
ES2968264T3 (es) * 2016-10-10 2024-05-08 Singapore Health Serv Pte Ltd Anticuerpos anti-CEACAM6 y métodos de utilización
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
JP7100028B2 (ja) 2016-10-20 2022-07-12 セルジーン コーポレイション セレブロン系のヘテロ二量体化可能なキメラ抗原受容体
DK3543337T3 (da) 2016-11-18 2022-05-09 Astellas Pharma Inc Hidtil ukendt fab-fragment af et anti-humant muc1-antistof
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
CN108440668A (zh) * 2017-02-16 2018-08-24 瑞阳(苏州)生物科技有限公司 Fgf21与igf-1的融合蛋白及其应用
CN110325209A (zh) 2017-02-24 2019-10-11 宏观基因有限公司 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
EP3398967A1 (fr) 2017-05-04 2018-11-07 B Cell Design Anticorps dirigés contre l'antigène carcino-embryonnaire pour le diagnostic et la thérapie du cancer
WO2019010222A2 (fr) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Polynucléotides codant pour des molécules de fusion immunostimulantes et leurs utilisations
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019014360A1 (fr) 2017-07-11 2019-01-17 Alexion Pharmaceuticals, Inc. Polypeptides se liant au composant c5 du complément ou à l'albumine sérique et protéines de fusion de ceux-ci
EP3694552A1 (fr) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
AU2018385409A1 (en) 2017-12-12 2020-07-02 Macrogenics Inc. Bispecific CD 16-binding molecules and their use in the treatment of disease
AU2019222666A1 (en) 2018-02-15 2020-09-03 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
MX2020012418A (es) 2018-05-23 2021-04-28 Adc Therapeutics Sa Adyuvante molecular.
EP3802599B1 (fr) 2018-06-03 2023-12-20 LamKap Bio beta AG Anticorps bispécifiques dirigés contre ceacam5 et cd47
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
JP2022502403A (ja) 2018-09-26 2022-01-11 アセンディス ファーマ エー／エス 分解性ヒアルロン酸ヒドロゲル
TWI835880B (zh) * 2018-10-10 2024-03-21 日商安斯泰來製藥股份有限公司 含有標識部－抗人類抗體Ｆａｂ片段複合體之醫藥組成物
JP2022504839A (ja) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド 抗ｌａｐ抗体変異体及びその使用
TW202100560A (zh) * 2019-06-04 2021-01-01 大陸商上海吉倍生物技術有限公司 一種抗ceacam5 的單殖株抗體及其製備方法和用途
CN110132937A (zh) * 2019-06-05 2019-08-16 福建师范大学 一种dna链作为信号开关检测重金属离子的制备方法
CN110327074A (zh) * 2019-08-02 2019-10-15 无锡海斯凯尔医学技术有限公司 肝脏评价方法、装置、设备及计算机可读存储介质
GB201911187D0 (en) 2019-08-05 2019-09-18 Autolus Ltd Receptor
JP2022548947A (ja) 2019-09-18 2022-11-22 ランカプ バイオ アルファ アーゲー Ｃｅａｃａｍ５およびｃｄ３に対する二特異性抗体
CN110713539B (zh) * 2019-09-23 2021-04-16 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
EP4034160A1 (fr) * 2019-09-27 2022-08-03 Janssen Biotech, Inc. Anticorps anti-ceacam et leurs utilisations
EP3831849A1 (fr) 2019-12-02 2021-06-09 LamKap Bio beta AG Anticorps bispécifiques contre ceacam5 et cd47
AU2021335257A1 (en) * 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
WO2022133169A1 (fr) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Systèmes récepteurs antigéniques chimériques ayant une spécificité de récepteur adaptable
IL301701A (en) 2020-12-18 2023-05-01 Lamkap Bio Beta Ag Bispecific antibodies against CEACAM5 and CD47
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN112557662B (zh) * 2021-02-22 2021-07-06 和卓生物科技（上海）有限公司 一种结直肠癌检测试剂盒
WO2023016488A1 (fr) 2021-08-13 2023-02-16 昆山新蕴达生物科技有限公司 Conjugué anticorps-médicament à base d'inhibiteur de microtubules
WO2023024949A1 (fr) 2021-08-24 2023-03-02 昆山新蕴达生物科技有限公司 Conjugué anticorps-médicament conjugué par l'intermédiaire d'un lieur cassable
CN115819596A (zh) * 2021-09-17 2023-03-21 优迈生物科技(连云港)有限公司 一种靶向人ceacam5/6的抗体、制备方法和应用
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
CN114560944B (zh) * 2022-03-30 2022-08-09 北京科跃中楷生物技术有限公司 胶体金颗粒标记的抗体及其应用
CN114409789B (zh) * 2022-03-30 2022-06-07 北京科跃中楷生物技术有限公司 一种胶体金颗粒标记方法及检测试剂盒
WO2023198019A1 (fr) * 2022-04-12 2023-10-19 盛禾(中国)生物制药有限公司 Anticorps dirigé contre ceacam5 et ceacam6 et son utilisation
WO2023242351A1 (fr) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Polythérapie d'anticorps bispécifiques dirigés contre ceacam5 et cd47 et anticorps bispécifiques dirigés contre ceacam5 et cd3
US20240124607A1 (en) 2022-08-10 2024-04-18 Merck Sharp & Dohme Llc Proteins binding nkg2d, cd16, and ceacam5
CN116731165A (zh) * 2023-03-23 2023-09-12 北京巴瑞医疗器械有限公司 一种抗血清素抗体及其应用

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US672015A (en) 1900-10-05 1901-04-16 Alfred Schlatter Automatic switch for groups of transformers.
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4818709A (en) 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US6861511B1 (en) 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6511665B1 (en) 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
US6432402B1 (en) 1989-05-25 2002-08-13 Sloan-Kettering Institute For Cancer Research Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
CA2033347C (fr) 1989-06-02 2000-02-29 James E. Hildreth Anticorps monoclonaux contre la chaine beta du recepteur responsable de l'adhesion des leucocytes, procede de fabrication et mode d'utilisation
US5081235A (en) 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
US7041293B1 (en) 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5854416A (en) 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
EP0672253A4 (fr) 1992-01-29 1995-12-06 Sci Clone Inc Antigene (sk1) associe au carcinome et anticorps monoclonaux diriges contre le sk1, procedes de production de ces anticorps et applications.
WO1993017694A1 (fr) 1992-03-09 1993-09-16 San Diego Regional Cancer Center Anticorps anti-idiotypique et utilisation diagnostique et therapeutique pour les affections dues au vih
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
ATE175241T1 (de) 1992-04-03 1999-01-15 Genentech Inc Antikörper gegen alpha v beta 3 integrin
EP0643583B1 (fr) 1992-05-06 2000-07-26 Immunomedics, Inc. Detection et therapie de tumeurs et de lesions pendant un examen peroperatoire, intravasculaire et endoscopique
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
IL109666A0 (en) 1993-05-17 1994-08-26 Immunomedics Inc A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof
ATE335072T1 (de) 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
WO1995007102A1 (fr) 1993-09-09 1995-03-16 Duke University Procede favorisant les fonctions cellulaires
AU1289795A (en) 1993-11-19 1995-06-06 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6432404B1 (en) 1993-12-23 2002-08-13 Icos Corporation Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies
US5922572A (en) 1994-01-25 1999-07-13 Human Genome Sciences, Inc. Polynucleotides encoding haemopoietic maturation factor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6100389A (en) 1995-04-21 2000-08-08 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic protein
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6709653B1 (en) 1994-09-16 2004-03-23 Human Genome Sciences, Inc. Antibodies specific for human inositol monophosphatase H1
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5750370A (en) 1995-06-06 1998-05-12 Human Genome Sciences, Inc. Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
US6538121B1 (en) 1994-11-01 2003-03-25 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
US5786204A (en) 1995-01-20 1998-07-28 Human Genome Sciences, Inc. Human prostatic specific reductase
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US6605441B1 (en) 1995-06-05 2003-08-12 Human Genome Sciences, Inc. Antibodies against fibroblast growth factor 11
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
AU6223296A (en) 1995-06-07 1996-12-30 Novartis Ag Methods for obtaining compositions enriched for hematopoieti c stem cells and antibodies for use therein
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5945309A (en) 1996-03-19 1999-08-31 Human Genome Sciences, Inc. Cytostatin III nucleic acids encoding
US6254868B1 (en) 1996-03-20 2001-07-03 Immunomedics, Inc. Glycosylated humanized B-cell specific antibodies
FR2746398B1 (fr) 1996-03-21 1998-04-30 Bio Merieux Anticorps specifique de staphylococcus aureaus, et utilisations
US6174992B1 (en) 1997-03-21 2001-01-16 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor I, II and III
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
US6110463A (en) 1996-03-29 2000-08-29 North Carolina State University Anti-Cryptosporidium parvum preparations
US6066617A (en) 1996-04-03 2000-05-23 Human Genome Sciences, Inc. Human cystatin F
WO1997041898A1 (fr) 1996-05-03 1997-11-13 Immunomedics, Inc. Immunotherapie-cible associee contre le cancer
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6764688B2 (en) 1996-09-03 2004-07-20 Kaneka Corporation Method for inducing immunosuppressive cells and a culture device to be used therefor
US6479247B1 (en) 1996-10-09 2002-11-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Dendritic cell-specific antibodies
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
WO1998021334A2 (fr) 1996-11-13 1998-05-22 Morphogenesis, Inc. Anticorps mg1 reconnaissant un petit sous-ensemble de cellules hematopoietiques humaines
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
AU6241698A (en) 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Tace-like and matrilysin-like polypeptides
EP1012274B2 (fr) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Recepteur 4 (dr4:recepteur 4 de mort cellulaire) contenant des domaines de mort cellulaire, membre de la superfamille du recepteur du facteur de necrose tumorale (tnf) et se liant a la trail ( apo-2l)
US6090381A (en) 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
JP2001523956A (ja) 1997-03-03 2001-11-27 ブリストル−マイヤーズ・スクイブ・カンパニー ヒトｃｄ６に対するモノクローナル抗体
US6919433B2 (en) 1997-03-14 2005-07-19 Human Genome Sciences, Inc. Antibodies to protein HPMBQ91
US6951924B2 (en) 1997-03-14 2005-10-04 Human Genome Sciences, Inc. Antibodies against secreted protein HTEBYII
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2288232A1 (fr) 1997-05-02 1998-11-12 The Government Of The United States, Represented By The Secretary, Depar Tment Of Health And Human Services Immunotoxines dirigees contre des cellules malignes
US6284474B1 (en) 1998-04-23 2001-09-04 The Regents Of The University Of California Detection and diagnosis of conditions associated with lung injury
US6372217B1 (en) 1997-06-03 2002-04-16 Regents Of The University Of Minnesota Methods for the treatment of CD7+ viral infection with TXU-7-PAP
US6545130B2 (en) 1997-06-04 2003-04-08 Albert Einstein College Of Medicine Of Yeshiva University Monoclonal antibodies to mycobacterium tuberculosis and a modified ELISA assay
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
DE69839401T2 (de) 1997-09-18 2009-05-07 Genentech Inc., San Francisco Dcr3 polypeptid, ein tnfr homolog
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU1682699A (en) 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US6861227B2 (en) 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
US6200765B1 (en) 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
US6458933B1 (en) 1998-05-20 2002-10-01 Immunomedics, Inc. Therapeutic using a bispecific antibody
US6881405B2 (en) 1998-06-15 2005-04-19 Altarex Medical Corp. Reagents and methods for inducing an immune response to prostate specific antigen
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US6528269B1 (en) 1998-06-22 2003-03-04 Case Western Reserve University Immunological agents specific for prion protein (PRP)
ATE460946T1 (de) 1998-06-22 2010-04-15 Immunomedics Inc Gebrauch von bispezifischen antikörpern in diagnose und therapie
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6692908B1 (en) 1998-11-05 2004-02-17 Stanford University Prevention and treatment of HCV infection employing antibodies that inhibit the interaction of HCV virions with their receptor
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
DE69930872T8 (de) 1998-12-21 2007-05-03 Ludwig Institute For Cancer Research Antikörper gegen verkürzten vegf-d und deren verwendungen
US6444790B1 (en) 1998-12-23 2002-09-03 Human Genome Sciences, Inc. Peptidoglycan recognition proteins
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
MXPA01010891A (es) 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CA2375912C (fr) 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b
US20020002270A1 (en) 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
US6355481B1 (en) 1999-06-18 2002-03-12 Emory University Hybridoma cell line and monoclonal antibody for huntingtin protein
US6964854B1 (en) 1999-07-13 2005-11-15 Science & Technology Corporation Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
US6376654B1 (en) 1999-08-13 2002-04-23 Molecular Discoveries, Llc Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
US6716966B1 (en) 1999-08-18 2004-04-06 Altarex Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
US6630144B1 (en) 1999-08-30 2003-10-07 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies to Ebola glycoprotein
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US6835370B2 (en) 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
US6319675B1 (en) 1999-11-24 2001-11-20 Millennium Pharmaceuticals, Inc. Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor
US6835549B2 (en) 2000-02-24 2004-12-28 University Of Medicine & Dentistry Of New Jersey Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma
ES2329010T3 (es) 2000-03-23 2009-11-20 Genentech, Inc. Inhibidores anti-c2/c2a de la activacion del complemento.
CA2408549A1 (fr) 2000-05-11 2001-11-15 Altarex Corp. Procede et composition therapeutiques faisant appel a un complexe antigene-anticorps et a sa presentation par les cellules dendritiques
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
AU2001278129A1 (en) 2000-07-31 2002-02-13 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Specific binding agents for kshv vil-6 that neutralize a biological activity
JP3888971B2 (ja) 2000-08-08 2007-03-07 イムノメディクス， インコーポレイテッド 慢性骨髄性白血病の免疫療法
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
WO2002029015A1 (fr) 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Dosage destine a la detection rapide de proteine c activees humaine et d'anticorps monoclonal specifiquement dirige contre cette proteine
CA2424379C (fr) 2000-10-10 2013-10-01 Tanox, Inc. Inhibition de l'activation du complement c5 pour le traitement et la prevention du rejet differe d'une xenogreffe ou d'un rejet vasculaire aigu
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
UY27087A1 (es) 2001-01-05 2002-06-20 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US6743898B2 (en) 2001-03-15 2004-06-01 Ochsner Clinic Foundation Monoclonal antibodies that suppress B cell growth and/or differentiation
US6824778B2 (en) 2001-04-23 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Prophylactic and therapeutic monoclonal antibodies
AU2002303832A1 (en) 2001-05-21 2002-12-03 Beth Israel Deaconess Medical Center, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides
US7151164B2 (en) 2002-02-14 2006-12-19 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US7049060B2 (en) 2001-11-05 2006-05-23 Ortho-Clinical Diagnostics, Inc. HCV anti-core monoclonal antibodies
EP2287201B1 (fr) 2002-03-01 2018-12-12 Immunomedics, Inc. Anticorps RS7
AU2003215732B2 (en) 2002-03-01 2009-12-17 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US7563433B2 (en) 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
EP2301968A3 (fr) 2002-06-14 2011-06-29 Immunomedics, Inc. Anticorps monoclonal humanisé HPAM4
WO2004013180A2 (fr) 2002-08-01 2004-02-12 Immunomedics, Inc. Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
EP1572131B1 (fr) 2002-10-08 2016-07-06 Immunomedics, Inc. Therapie fondee sur les anticorps
JP4511356B2 (ja) * 2002-10-08 2010-07-28 イミューノメディクス、インコーポレイテッド クラスｉｉｉ抗ｃｅａモノクローナル抗体と治療薬とを用いる併用治療
HUE034378T2 (en) 2002-10-16 2018-02-28 Purdue Pharma Lp Cell-associated CA 125 / O722P binding antibodies and methods of use
DE60332957D1 (de) * 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
CN1745104A (zh) 2003-01-28 2006-03-08 先灵公司 特异于类浆细胞树突状细胞的抗体
CN1767860A (zh) 2003-01-31 2006-05-03 免疫医疗公司 施用治疗和诊断剂的方法和组合物
CA2534639C (fr) 2003-07-31 2013-07-30 Immunomedics, Inc. Anticorps anti-cd19
WO2006107617A2 (fr) 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methodes de generation de complexes lies stablement composes d'homodimeres, d'homotetrameres ou de dimeres de dimeres et utilisations associees
US7608425B2 (en) 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
DE602005026219D1 (de) 2004-10-01 2011-03-17 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
DK3332808T3 (da) 2005-03-03 2020-12-14 Immunomedics Inc Humaniserede L243-antistoffer
JP5399712B2 (ja) * 2005-12-21 2014-01-29 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬組成物
WO2007098283A2 (fr) 2006-02-27 2007-08-30 Biogen Idec Ma Inc. Utilisation d'antagonistes de molécules complexes du récepteur maif (macrophage migration-inhibitory factors) et de facteurs neurotrophiques pour traiter des maladies et des troubles neurologiques
CN102159243B (zh) 2008-07-21 2015-08-19 免疫医疗公司 用于改良的治疗特征的抗体的结构变体
IN2012DN01663A (fr) * 2009-09-16 2015-06-05 Immunomedics Inc
AU2014214843A1 (en) * 2013-02-07 2015-05-21 Immunomedics, Inc. Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Also Published As

Publication number Publication date
US8470994B2 (en) 2013-06-25
US20130034492A1 (en) 2013-02-07
CA2774260C (fr) 2018-10-09
US20110064653A1 (en) 2011-03-17
US20140079629A1 (en) 2014-03-20
US8771690B2 (en) 2014-07-08
WO2011034660A1 (fr) 2011-03-24
US20130344071A1 (en) 2013-12-26
CA2774260A1 (fr) 2011-03-24
EP3009455A1 (fr) 2016-04-20
EP2478110A4 (fr) 2013-11-27
CN102482701A (zh) 2012-05-30
US9371393B2 (en) 2016-06-21
CN102482701B (zh) 2015-05-13
EP2478110B1 (fr) 2016-01-06
US20150343087A1 (en) 2015-12-03
US20140308278A1 (en) 2014-10-16
EP2478110A1 (fr) 2012-07-25
US8287865B2 (en) 2012-10-16
US8603479B1 (en) 2013-12-10
US9139657B2 (en) 2015-09-22
US8945554B2 (en) 2015-02-03
US20150111279A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
IN2012DN01663A (fr)
HUS2200044I1 (hu) Humanizált anti-CD19 ellenanyagok és használatuk daganatokban, transzplantációknál és autoimmun betegségekben
Münz et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
EP1996716A4 (fr) Anticorps modifies diriges contre l'antigene de cellules souches prostatiques servant a cibler le cancer
IN2012DN05101A (fr)
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
RU2017116847A (ru) Антитела к pd-1
MY160892A (en) Antibodies to ccr2
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
EA200970130A1 (ru) Антагонистическое антитело для лечения рака
WO2006099141A3 (fr) Anticorps diriges contre la mesotheline
WO2013173496A3 (fr) Anticorps cd33 et leur utilisation pour traiter le cancer
HK1071576A1 (en) Internalizing anti-cd74 antibodies and methods of use
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
MX340724B (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama.
MX344971B (es) Anticuerpos anti-ctla4 humanizados.
WO2010017500A3 (fr) Anticorps anti-cancer pancréatique
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
TW200720289A (en) Antibodies against CCR5 and uses thereof
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ717213A (en) Anti-pd-l1 antibodies and their use to enhance t-cell function
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ603455A (en) Anti-human trop-2 antibody having antitumor activity in vivo